Xiujiang Susie Li

Statistics

Publications

Citations

130

H-Index

Active since

2013

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Cornell University

Foundation for Biomedical Research

Executive Office of the President

UNSW Sydney

Xiujiang Susie Li is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, lipid-lowering drug efficacy, and clinical pharmacology.

Publications per year

2013–2014

Publications

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

Antonio M. Gotto, Christopher P. Cannon, Xiujiang Susie Li et al. · The American Journal of Cardiology · 2013 · 86 citations

Medicine, Cardiology, Pharmacology +17

Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

Antonio M. Gotto, Uma Kher, Manash Chatterjee et al. · Journal of Cardiovascular Pharmacology and Therapeutics · 2014 · 44 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

1–2 of 2